OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
April 01, 2012
Come Rain or Shine
Throughout her life, HBA Woman of the Year Carolyn Buck-Luce has made progress by recognizing that when one door closes, another one opens.
What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK?
India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries.
Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.
This year's Ad Stars embrace creativity through the eyes of the patients. Ben Comer and Jennifer Ringler report.
Phase in of the Sunshine Act will force a reconsideration of the ethical consequences of all types of pharma meetings. How and to what extent remains to be seen.
While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
Too often in M&A or product-linked carve-outs, executives overlook the complexities of disentangling operations and the effort required for regulatory re-registration and labeling changes.
Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts
While what is considered 'traditional' marketing has evolved over the years, it's clear that a digital strategy is an absolute necessity to compete today-not just tomorrow.
Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.